NEW YORK (AP) — Horizon Pharma boosted its full-year sales forecast on Tuesday, citing its expected closing of the $510 million acquisition of Crealta Holdings LLC this week.
Shares of the Dublin-based company rose more than 7 percent in premarket trading.
Horizon Pharma PLC now anticipates full-year sales between about $1.03 billion and $1.05 billion. Its prior guidance was for sales in a range of $950 million to $975 million.
Analysts surveyed by FactSet expect $987.3 million.
Horizon Pharma's stock added $1.30, or 7.2 percent, to $19.39 in premarket dealings before the market open Tuesday. Its shares have risen 28 percent over the past year.